e15v12b
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-11397
VALEANT PHARMACEUTICALS INTERNATIONAL
 
(Exact name of registrant as specified in its charter)
One Enterprise
Aliso Viejo, California 92656
(949) 461-6000
 
(Address, including zip code, and telephone number, including area code, of
registrant’s principal executive offices)
8.375% Senior Notes due 2016
 
(Title of each class of securities covered by this Form)
None
 
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains)
     Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
     
Rule 12g-4(a)(1)
  o
Rule 12g-4(a)(2)
  o
Rule 12h-3(b)(1)(i)
  þ
Rule 12h-3(b)(1)(ii)
  o
Rule 15d-6
  o
     Approximate number of holders of record as of the certification or notice date: none
     Pursuant to the requirements of the Securities Exchange Act of 1934, Valeant Pharmaceuticals International has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
         
     
October 27, 2010  By:   /s/ Robert Chai-Onn    
    Robert Chai-Onn   
    Executive Vice President, General Counsel
and Corporate Secretary